The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩4,714.75Fair value₩14,896.80Bull₩21,096.84
FairClose
52-week traded range
52W low ₩6,290.0052W high ₩9,280.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
JEIL PHARMA HOLDINGS INC. closed at ₩7,680.00, 48.4% below the consensus fair value of ₩14,896.80 drawn from 7 valuation models.
Financial DNA score 37/100 — Average. P/E of 8.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩17,861.64
+132.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩21,096.84
+174.7%
√(22.5 × EPS × BVPS)
EPS=953, BVPS=20756.76
P/E Fair Value
₩19,060.00
+148.2%
EPS × 20x (sector P/E)
EPS=953, Sector P/E=20x
EV/EBITDA
₩6,074.24
-20.9%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=38.69B
Book Value (P/B)
₩4,714.75
-38.6%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=20756.76, ROE=4.6%, g=3%, r=10%
Reverse DCF
₩7,680.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -5.4% | Historical: 0%
Margin of Safety
₩14,504.62
+88.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=19339.49, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.